Accordingly, abemaciclib demonstrated significantly higher ORRs and PFS than erlotinib in pretreated patients with advanced-stage KRAS-mutant lung cancer patients, but no significant difference was observed in OS [93, 94]. This evidence concerns the gene KRAS and lung carcinoma.